Inflammation and Bone Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 139-141

  Hill, Geoffrey R ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen presenting cell; Cytokine; Graft versus host disease; Inflammation; T cell

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HUMAN; INFLAMMATION; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; T LYMPHOCYTE ACTIVATION; WHOLE BODY RADIATION;

EID: 64749102801     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.008     Document Type: Article

References (25)

1. Holler E., Kolb H.J., Mittermueller J., et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor a (TNFa) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 86 (1995) 890-899
2. Hill G.R., Cooke K.R., Teshima T., et al. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 67 (1999) 1478-1480
3. Banovic T., MacDonald K.P., Morris E.S., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood 106 (2005) 2206-2214
4. Remberger M., Ringden O., and Markling L. TNFa levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 15 (1995) 99-104
5. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
6. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft-versus-host disease by inactivation of host antigen presenting cells. Science 285 (1999) 412-415
7. + T cells do not induce graft-versus-host disease. J Clin Invest 112 (2003) 101-108
8. Hill G.R., Teshima T., Gerbita A., et al. Differential roles of IL-1 and TNFa on graft-versus-host disease and graft-versus-leukemia. J Clin Invest 104 (1999) 459-467
9. Hill G.R., Crawford J.M., Cooke K.J., et al. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
10. Nestel F.P., Price K.S., Seemayer T.A., et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175 (1992) 405-413
11. Hill G.R., and Ferrara J.L.M. The primacy of the gastrointestinal tract as a target organ of graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
12. Morris E.S., and Hill G.R. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 137 (2007) 3-19
13. Schmaltz C., Alpdogan O., Muriglan S.J., et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 101 (2003) 2440-2445
14. Borsotti C., Franklin A.R., Lu S.X., et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood 110 (2007) 783-786
15. Cooke K.R., Hill G.R., Gerbitz A., et al. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J Immunol 165 (2000) 6612-6619
16. Hill G.R., Rebel V., Teshima T., et al. The p55 TNFa receptor plays a critical role in T cell alloreactivity. J Immunol 164 (2000) 656-663
17. Murphy W.J., Welniak L.A., Taub D.D., et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 102 (1998) 1742-1748
18. Nikolic B., Lee S., Bronson R.T., et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 105 (2000) 1289-1298
19. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002) 575-581
20. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112 (2008) 1539-1542
21. Antin J.H., Weisdorf D., Neuberg D., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100 (2002) 3479-3482
22. Burman A.C., Banovic T., Kuns R.D., et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 110 (2007) 1064-1072
23. Delisle J.S., Gaboury L., Belanger M.P., et al. Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts. Blood 112 (2008) 2111-2119
24. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110 (2007) 237-241
25. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606